Nadolol

Nadolol (Corgard, Anabet, Solgol, Corzide, Alti-Nadolol, Apo-Nadol, Novo-Nadolol) je neselektivni beta blokator koji se koristi za lečenje visokog krvnog pritiska, migrenskih glavobolja, i bola u grudima.^[6][7]

Nadolol

(IUPAC) ime
rel-(2R,3S)-5[(2R)-3-(tert-butilamino)-2-hidroksipropil]oksi1,2,3,4-tetrahidronafthalen-2,3-diol (2R*,3S*)-5[(2R*)-3-(tert-butilamino)-2-hidroksipropil]oksi1,2,3,4-tetrahidronafthalen-2,3-diol
Klinički podaci
Robne marke	Corgard
AHFS/Drugs.com	Monografija
MedlinePlus	a682666
Identifikatori
CAS broj	42200-33-9
ATC kod	C07AA12
PubChem[1][2]	39147
DrugBank	DB01203
ChemSpider[3]	35815
UNII	FEN504330V Y
KEGG[4]	D00432 Y
ChEMBL[5]	CHEMBL649 Y
Hemijski podaci
Formula	C17H27NO4
Mol. masa	309,401 g/mol
SMILES	eMolekuli & PubHem
Farmakokinetički podaci
Vezivanje za proteine plazme	30%
Metabolizam	Nil
Poluvreme eliminacije	14-24 sata
Izlučivanje	Renalno i fekalno (nepromenjen)
Farmakoinformacioni podaci
Trudnoća	C(US)
Pravni status	POM (UK) ℞-only (SAD)
Način primene	Oralnot

Povezano

• Beta blokator

Reference

1. Li Q, Cheng T, Wang Y, Bryant SH (2010). „PubChem as a public resource for drug discovery.”. Drug Discov Today 15 (23-24): 1052-7. DOI:10.1016/j.drudis.2010.10.003. PMID 20970519. edit
2. Evan E. Bolton, Yanli Wang, Paul A. Thiessen, Stephen H. Bryant (2008). „Chapter 12 PubChem: Integrated Platform of Small Molecules and Biological Activities”. Annual Reports in Computational Chemistry 4: 217-241. DOI:10.1016/S1574-1400(08)00012-1.
3. Hettne KM, Williams AJ, van Mulligen EM, Kleinjans J, Tkachenko V, Kors JA. (2010). „Automatic vs. manual curation of a multi-source chemical dictionary: the impact on text mining”. J Cheminform 2 (1): 3. DOI:10.1186/1758-2946-2-3. PMID 20331846. edit
4. Joanne Wixon, Douglas Kell (2000). „Website Review: The Kyoto Encyclopedia of Genes and Genomes — KEGG”. Yeast 17 (1): 48–55. DOI:10.1002/(SICI)1097-0061(200004)17:1<48::AID-YEA2>3.0.CO;2-H.
5. Gaulton A, Bellis LJ, Bento AP, Chambers J, Davies M, Hersey A, Light Y, McGlinchey S, Michalovich D, Al-Lazikani B, Overington JP. (2012). „ChEMBL: a large-scale bioactivity database for drug discovery”. Nucleic Acids Res 40 (Database issue): D1100-7. DOI:10.1093/nar/gkr777. PMID 21948594. edit
6. Hardman JG, Limbird LE, Gilman AG. (2001). Goodman & Gilman's The Pharmacological Basis of Therapeutics (10 izd.). New York: McGraw-Hill. DOI:10.1036/0071422803. ISBN 0-07-135469-7.
7. Pdr Staff (2009). PDR: Physicians Desk Reference 2010 (Physicians' Desk Reference (Pdr)). Rozelle, N.S.W: Thomson Reuters. ISBN 1-56363-748-0.

Literatura

• Buice RG, Subramanian VS, Duchin KL, Uko-Nne S. (1996). „Bioequivalence of a highly variable drug: an experience with nadolol”. Pharmaceutical Research 13 (7): 1109–15. DOI:10.1023/A:1016031313065. PMID 8842054.
• N. Hanania, S. Singh, R. El-Wali, et al. The safety and effects of the beta-blocker, nadolol, in mild asthma: An open-label pilot study, Pulmonary Pharmacology & Therapeutics, Volume 21, Issue 1, Pages 134-141

Vanjske veze

	Portal Medicina
	Portal Hemija

• Nadolol Arhivirano 2007-08-22 na Wayback Machine-u